Pharmapack Europe: Innovation, Networking and Education pharmiweb.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pharmiweb.com Daily Mail and Mail on Sunday newspapers.
Feb 2, 2021
MONDAY, Feb. 1, 2021 (HealthDay News) For patients with cirrhosis undergoing transjugular intrahepatic portosystemic shunt (TIPS) placement, rifaximin used before and after the procedure is associated with a reduced risk for overt hepatic encephalopathy (HE), according to a study published online Feb. 2 in the
Annals of Internal Medicine.
Christophe Bureau, M.D., Ph.D., from the University Hospital of Toulouse in France, and colleagues conducted a randomized, placebo-controlled trial to examine whether rifaximin prevents overt HE after TIPS. One hundred ninety-seven patients with cirrhosis undergoing TIPS for intractable ascites or prevention of variceal rebleeding were enrolled and randomly assigned to receive either rifaximin or placebo starting 14 days before TIPS and continuing for 168 days after TIPS.